First National Trust Co Decreases Stock Holdings in Edwards Lifesciences Corporation $EW

First National Trust Co reduced its position in shares of Edwards Lifesciences Corporation (NYSE:EW) by 13.0% in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 3,224 shares of the medical research company’s stock after selling 480 shares during the quarter. First National Trust Co’s holdings in Edwards Lifesciences were worth $252,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also added to or reduced their stakes in the company. Allspring Global Investments Holdings LLC boosted its holdings in shares of Edwards Lifesciences by 0.5% during the first quarter. Allspring Global Investments Holdings LLC now owns 30,195 shares of the medical research company’s stock worth $2,170,000 after purchasing an additional 145 shares during the period. Pacific Capital Partners Ltd purchased a new stake in Edwards Lifesciences in the 2nd quarter worth approximately $1,760,000. Czech National Bank grew its position in shares of Edwards Lifesciences by 5.8% in the 2nd quarter. Czech National Bank now owns 143,385 shares of the medical research company’s stock worth $11,214,000 after buying an additional 7,917 shares during the last quarter. Mirova US LLC grew its position in shares of Edwards Lifesciences by 56.2% in the 2nd quarter. Mirova US LLC now owns 2,931,297 shares of the medical research company’s stock worth $229,257,000 after buying an additional 1,054,301 shares during the last quarter. Finally, Wealth Enhancement Advisory Services LLC increased its stake in shares of Edwards Lifesciences by 111.9% during the second quarter. Wealth Enhancement Advisory Services LLC now owns 163,202 shares of the medical research company’s stock valued at $12,532,000 after buying an additional 86,186 shares during the period. Institutional investors own 79.46% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages recently commented on EW. JPMorgan Chase & Co. raised their price target on Edwards Lifesciences from $80.00 to $85.00 and gave the stock a “neutral” rating in a research note on Friday, July 25th. The Goldman Sachs Group reiterated a “buy” rating on shares of Edwards Lifesciences in a research report on Friday, July 25th. Mizuho raised their price objective on shares of Edwards Lifesciences from $87.00 to $95.00 and gave the stock an “outperform” rating in a report on Friday, July 25th. Daiwa America raised Edwards Lifesciences from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, July 29th. Finally, Barclays raised their target price on Edwards Lifesciences from $90.00 to $95.00 and gave the company an “overweight” rating in a research note on Friday, July 25th. Three equities research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, eight have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $87.89.

Edwards Lifesciences Stock Up 0.7%

EW stock opened at $82.73 on Thursday. The business has a 50 day moving average of $77.52 and a 200 day moving average of $76.75. The firm has a market cap of $48.57 billion, a PE ratio of 11.90, a price-to-earnings-growth ratio of 3.94 and a beta of 1.05. Edwards Lifesciences Corporation has a twelve month low of $64.89 and a twelve month high of $84.66. The company has a quick ratio of 3.87, a current ratio of 4.68 and a debt-to-equity ratio of 0.06.

Insider Activity

In other news, insider Larry L. Wood sold 8,950 shares of Edwards Lifesciences stock in a transaction dated Monday, August 18th. The stock was sold at an average price of $78.06, for a total value of $698,637.00. Following the completion of the transaction, the insider owned 206,900 shares of the company’s stock, valued at $16,150,614. The trade was a 4.15% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 1.29% of the stock is currently owned by corporate insiders.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.